Compare Johnson & Johnson (JNJ) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Manulife Financial Corporation — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Manulife Financial Corporation trades at $42.43 (market cap $69.48B). The key difference: Johnson & Johnson is far larger — about 8.9× Manulife Financial Corporation's market cap, and Manulife Financial Corporation pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Manulife Financial Corporation for 119 Days on average.
| JNJ | MFC | |
|---|---|---|
Market Cap | $618.09B | $69.48B |
Volume | 6,050,983 | 1,347,508 |
Sector | Health | Financials |
52-Week High | $278.43 | $44.77 |
52-Week Low | $186.00 | $31.64 |
Typical Hold Time | 129 Days | 119 Days |
Enterprise Value | $646.37B | $64.75B |
Dividend Yield | 2.09% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
MFC trades at $42.12, up 1.08% today, with a bearish technical signal from moving averages. Revenue grew to $53.01B in 2025, with a net income margin of 11.7%, while Q2 2026 earnings beat expectations. Analyst consensus is bullish with 57% buy ratings, though the consensus price target of $34.24 is below the current price. Recent news includes a new $750M subordinated notes offering and executive appointments.
Outlook is mixed: strong fundamentals and institutional interest support upside, but technical weakness and a high valuation relative to the price target pose risks. Key catalysts include Q3 2026 earnings and execution of growth initiatives in Asia.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
